CYP2A6 and the plasma level of 5-chloro-2, 4-dihydroxypyridine are determinants of the pharmacokinetic variability of tegafur and 5-fluorouracil, respectively, in Japanese patients with cancer given S-1.

doi:10.1111/j.1349-7006.2008.00773.x

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

CYP2A6 and the plasma level of 5-chloro-2, 4-dihydroxypyridine are determinants of the pharmacokinetic variability of tegafur and 5-fluorouracil, respectively, in Japanese patients with cancer given S-1.

Cancer science - 1 May 2008

Fujita Ken-ichi, Yamamoto Wataru, Endo Shoji, Endo Hisashi, Nagashima Fumio, Ichikawa Wataru, Tanaka Ryuhei, Miya Toshimichi, Araki Kazuhiro, Kodama Keiji, Sunakawa Yu, Narabayashi Masaru, Miwa Keisuke, Ando Yuichi, Akiyama Yuko, Kawara Kaori, Kamataki Tetsuya, Sasaki Yasutsuna

Abstract excerpt

S-1 is an oral anticancer agent composed of tegafur (FT), 5-chloro-2,4-dihydroxypyridine (CDHP), and potassium oxonate. CDHP is added to prevent degradation of 5-fluorouracil (5-FU) by inhibiting dihydropyrimidine dehydrogenase. CYP2A6 is involved in the biotransformation of FT to 5-FU. Thus, we prospectively analyzed the effects of the CYP2A6 genotype, plasma level of CDHP, and patient characteristics on the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antimetabolites, Antineoplastic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Aryl Hydrocarbon Hydroxylases

Share to Cytochrome P-450 CYP2A6

Share to Drug Combinations

Share to Fluorouracil

Share to Mixed Function Oxygenases

Share to Neoplasms

Share to Pyridines

Source

Open in PubMed Open full text

Identifiers

PMID: 18380793
DOI: 10.1111/j.1349-7006.2008.00773.x
PMCID: PMC11158323

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CYP2A6 and the plasma level of 5-chloro-2, 4-dihydroxypyridine are determinants of the pharmacokinetic variability of tegafur and 5-fluorouracil, respectively, in Japanese patients with cancer given S-1.PMID 18380793Read ↗

Pharmacokinetics of S-1 and CYP2A6 genotype in Japanese patients with advanced cancer.Semantic proximity Read ↗

The CYP2A6*4 allele is determinant of S-1 pharmacokinetics in Japanese patients with non-small-cell lung cancer.Semantic proximity Read ↗

Characteristic CYP2A6 genetic polymorphisms detected by TA cloning-based sequencing in Chinese digestive system cancer patients with S-1 based chemotherapy.Semantic proximity Read ↗

A novel mutant allele of the CYP2A6 gene (CYP2A6*11 ) found in a cancer patient who showed poor metabolic phenotype towards tegafur.Semantic proximity Read ↗

Associations between CYP2A6 polymorphisms and outcomes of adjuvant S-1 chemotherapy in patients with curatively resected gastric cancer.Semantic proximity Read ↗

Can the 2-(13)C-uracil breath test be used to predict the effect of the antitumor drug S-1?Semantic proximity Read ↗

Comparison of the pharmacokinetics and pharmacodynamics of S-1 between Caucasian and East Asian patients.Semantic proximity Read ↗

Association analysis of CYP2A6 genotypes and haplotypes with 5-fluorouracil formation from tegafur in human liver microsomes.Semantic proximity Read ↗

[The influence of CYP2A6 polymorphism on adjuvant S-1 chemotherapy outcomes in patients with curatively resected gastric cancer].Semantic proximity Read ↗

Genotype-phenotype correlations in 5-fluorouracil metabolism: a candidate DPYD haplotype to improve toxicity prediction.Semantic proximity Read ↗

Functional Characterization of 21 Allelic Variants of Dihydropyrimidine Dehydrogenase Identified in 1070 Japanese Individuals.Semantic proximity Read ↗

Population pharmacokinetics of gemcitabine and its metabolite in Japanese cancer patients: impact of genetic polymorphisms.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.